Key Benefits of PET in ccRCC Risk Stratification

EP: 1.The Evolvement of Imaging in ccRCC

EP: 2.The Biggest Challenges in Distinguishing ccRCC From Benign Renal Masses

EP: 3.Strengths and Weaknesses of Imaging Modalities in ccRCC

EP: 4.Treatment or Lack of Treatment of Small Renal Masses

EP: 5.Decision-Making in Small Renal Masses

EP: 6.Current Unmet Needs in ccRCC Diagnosis

EP: 7.Early Detection of ccRCC

Now Viewing

EP: 8.Key Benefits of PET in ccRCC Risk Stratification

EP: 9.The ZIRCON Trial

EP: 10.The MOA of TLX250

PET Imaging in Kidney Cancer Evaluation

Main Discussion Topics:

• Prostate-specific membrane antigen (PSMA) expression in renal cell carcinoma (RCC) was an incidental finding but shows potential.
• Uncertainty regarding frequency of PSMA expression across RCC subtypes
• Fluorodeoxyglucose (FDG) PET has limited utility in most RCC cases but may help characterize indeterminate lymph nodes or lung lesions.
• FDG PET shows particular value in rare FH-deficient tumors, which demonstrate intense uptake.

Key Points for Physicians:

• PSMA PET shows promise but lacks sufficient data for routine clinical use.
• FDG PET has limited utility in conventional RCC.
• FDG PET demonstrates high value in rare hereditary RCC variants with SDH or FH mutations.
• Current molecular imaging techniques provide adjunctive rather than primary diagnostic value.

Notable Insights:

Although molecular imaging shows promise, current modalities have significant limitations and are primarily useful in specific clinical scenarios.

Clinical Significance:

Molecular imaging techniques remain investigational for most RCC applications but show the potential to transform staging and characterization